MSD Korea’s sales 7%↓ due to the transfer of Januvia sales
By Son, Hyung-Min | translator Kim, Jung-Ju
24.04.13 05:50:30
가나다라
0
The sales of MSD Korea last year amounted to KRW 760.9 billion…a 7.3% decline YoY
It sold the sales rights of the Januvia series+Lagevrio’s sales decline might have also contributed to the decline in sales
The sales of cancer immunotherapy 'Keytruda' surged from KRW 239.6 billion→ KRW 298.7 billion
The sales of MSD Korea last year declined by 7.3% year-over-year (YoY).
The sales of cancer immunotherapy 'Keytruda' have increased significantly, while the sales of COVID-19 treatment 'Lagevrio' have decreased. The company’s external growth appears to have stalled. Moreover, the transfer of local sales rights of a diabetes drug 'Januvia' series to Chon Kung Dang Pharmaceutical might have also contributed to the decline in sales.
According to the Financial Supervisory Service on April 13th, MSD Korea recorded KRW 760.9 billion last year, down 7.3% from KRW 820.4 in 2022. Its revenue amounted to KRW 27.4 billion, down 4.2% YoY.
▲The trend in MSD Korea’s sales performance (unit: KRW 100 million ).
MSD Korea’s sales were KRW 471.6 bill
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)